This split-mouth trial investigated the efficacy of treating bilateral gingival recessions with either a xenogeneic cross-linked collagen matrix (CCM), or recombinant human platelet derived growth factor (rhPDGF-BB) with a bone allograft (AG). Ten patients were treated with the coronally advanced flap (CAF), either with a CCM, or rhPDGF-BB + AG. The primary outcome was percentage of mean root coverage (mRC) at 12 months.  Additional outcomes included clinical, volumetric, patient-reported outcome measures (PROMs) and ultrasonographic assessment of gingival thickness (GT) and position of the buccal bone (uBD). At 12 months, both groups showed significant improvements, with a mRC of 78.6% in the CCM group, and 82.3% for the rhPDGF-BB + AG sites. 3D analysis of both groups showed comparable volumetric gain. CCM-treated sites displayed higher ultrasonographic echogenicity in GT (p<.01) than rhPDGF-BB + AG sites. The rhPDGF-BB + AG group showed greater reduction in the buccal bone dehiscence (mean 2.03 mm, p<0.01), less swelling during the first three days, and slighty greater mean root coverage. CCM and rhPDGF-BB + AG showed to be effective in the treating multiple adjacent gingival recessions. CCM promotes greater gain in gingival thickness, while rhPDGF-BB + AG resulted in a significantly less buccal bone dehiscense.